{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '2nd. Annualized rate of severe exacerbation events during the 52-week placebo-controlled', 'treatment period based on the patients with baseline blood eosinophils >150 cells/L.', '3rd. Annualized rate of severe exacerbation events during the 52-week placebo-controlled', 'treatment period based on the patients with baseline blood eosinophils >300 cells/L.', 'Multiplicity control for any secondary endpoints if considered will be specified in the SAP.', 'Otherwise, nominal p-values will be provided.', '11.4.2.4 Handling of Missing Data', 'If patients withdraw from the study before Week 52 with severe exacerbation events that may', 'occur after study discontinuation (not being observed or without any FEV1 measurements', 'available after withdrawal), these patients are considered as patients with missing data on severe', 'exacerbation or on FEV1 % predicted. Number, reasons and timing of the missing data will be', 'summarized by treatment groups. In the primary analysis for the primary endpoint of severe', 'exacerbation, all observed data will be used regardless of treatment adherence or increase of', 'asthma background medication. No imputation will be conducted for the missing severe', 'exacerbation information after a patient prematurely withdraws from the study up to Week 52. In', 'the primary analysis for the key secondary endpoints of change from baseline in FEV1 %', 'predicted, all data up to Weeks 12 will be included in MMRM model. No additional imputation', 'will be conducted.', 'In addition, sensitivity analyses for the primary endpoint and the key secondary endpoints may be', 'performed based on a careful examination of the reason and pattern of missing data as described', 'in Section 11.4.2.1.1 and Section 11.4.2.2.5. Further details will be specified in the SAP.', '11.4.3 Analyses of Safety Data', 'The summary of safety results will be presented by treatment group. All safety analyses will be', 'performed on the safety population according to the following observation period definition.', 'The observation period will be divided into 4 epochs:', 'The screening epoch is defined as the time from the signed informed consent date up to the', 'time prior to first administration of the IMP.', 'The treatment epoch is defined as the time from the first administration of the IMP to the', 'last administration of the IMP + 14 days', 'The residual treatment epoch is defined as the time from the last administration of the', 'IMP + 15 days to the last administration of the IMP + 98 days.', 'The post-treatment epoch is defined as the period of time starting the day after the end of', 'the TEAE period up to the end of the study (defined as last protocol planned visit or the', 'resolution/stabilization of all serious adverse events and AESIs).', 'The TEAE period will include both treatment and residual treatment epochs.', 'Property of the Sanofi Group - strictly confidential', 'Page 117', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'The on-study observation period is defined as the time from start of treatment until the end of the', 'study (defined as last protocol planned visit or lost to follow-up or the resolution/stabilization of', 'all SAE and AESI.', 'All safety analyses will be performed on the safety population using the following common rules:', 'The baseline value is defined generally as the last available value before the first dose of', 'study drug.', 'The following definitions will be applied to laboratory parameters, vital signs and ECG.', '-', 'The potentially clinically significant abnormality (PCSA) values are defined as', 'abnormal values considered medically important by the Sponsor according to', 'predefined criteria/thresholds based on a review of the literature and defined by the', 'Sponsor for clinical laboratory tests, vital signs, and ECG.', '-', 'The criteria for PCSA will determine which patients had at least 1 PCSA during the', 'treatment-emergent period, taking into account all evaluations performed during the', 'on-treatment period, including unscheduled or repeated evaluations. The number of all', 'such patients will be the numerator for the on-treatment PCSA percentage.', '11.4.3.1 Adverse Events', 'Adverse event incidence tables will present by system organ class (SOC) (sorted by', 'internationally agreed order), high-level group term (HLGT), high level term (HLT), and', 'preferred term (PT) sorted in alphabetical order for each treatment group, the number (n) and', 'percentage (%) of patients experiencing an AE. Multiple occurrences of the same event in the', 'same patient will be counted only once in the tables within a treatment phase. The denominator', 'for computation of percentages is the safety population within each treatment group.', 'The proportion of patients with at least 1 TEAE, serious TEAE, and TEAE leading to', 'discontinuation of the study will be tabulated by treatment group. In addition, TEAEs will be', 'described according to maximum intensity and relation to the study drug. Serious AEs and AEs', 'leading to study discontinuation that occur outside the treatment-emergent period will be', 'summarized separately.', '11.4.3.1.1 Adverse Events of Special Interest', 'The following summaries will be generated:', 'Incidence of each AESI will be tabulated by treatment group.', 'An overview summary of the number (%) of patients with', '-', 'any AESI', '-', 'any serious AESI (regardless of treatment-emergent status)', '-', 'any treatment-emergent serious AESI', '-', 'any AESI leading to death', 'Property of the Sanofi Group - strictly confidential', 'Page 118', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}